CapitalSouth Announces Successful Exit of Portfolio Company, Quincy Bioscience, LLC

September 16, 2015

CapitalSouth SBIC Fund IV, L.P. (the “CapitalSouth Growth Fund”) announced today that it has recently exited its investment in Quincy Bioscience, LLC (“Quincy”), a biotechnology company that focuses on the discovery, development and commercialization of the branded supplement to support cognitive function and brain health.

Headquartered in Madison, Wisconsin, Quincy’s flagship product is Prevagen, which contains the patent-protected compounds apoaequorin and aequorin that alleviate impaired calcium homeostasis and improve mental function. Products are distributed through brick-and-mortar retail channels, such as CVS, Walgreens, and Rite Aid.

About CapitalSouth Growth Fund:
CapitalSouth Growth Fund and its CapitalSouth Partners predecessors were founded as early as 1998 to provide financial solutions to lower middle-market companies. The CapitalSouth Growth Fund invests in mature companies, making debt and equity investments typically between $2 million and $10 million and invests in a variety of industries throughout the United States. To learn more about CapitalSouth Growth Fund, please visit

About Capitala Group:
Capitala Group is a leading provider of capital to lower and traditional middle-market companies, through its family of credit focused funds. Since 1998, Capitala Group's managed funds have participated in over 100 transactions, representing approximately $900 million of investments in a variety of industries throughout North America. Capitala Group manages both public capital (Capitala Finance Corp. (Nasdaq:CPTA)) and private capital (including but not limited to the CapitalSouth Growth Fund) for its investors and seeks to partner with strong management teams to create value and serve as long term partners.